Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-24

FDA Approved: ONGENTYS — Original Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

FDA approved Ongentys (opicapone) as an add-on therapy to levodopa/carbidopa for adults with Parkinson's disease experiencing motor fluctuations ('off' episodes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ONGENTYS (opicapone)

Snippet

ORIG AP for ONGENTYS (OPICAPONE)